The MTHFR C677T Polymorphism and Risk of Intracerebral Hemorrhage in a Chinese Han Population

Xin Hu*
Chuanyuan Tao*
Zhiyi Xie
Yunke Li
Jun Zheng
Yuan Fang
Sen Lin
Hao Li
Chao You

* These authors contributed equally to this work

Corresponding Author: Chao You; e-mail: youchao_nswc@163.com; Hao Li; e-mail: coscolh@163.com

Source of support: The study was supported by the National Key Technology R&D Program for the 12th Five-year Plan of P.R. China (No. 2011BAI08B05) and the Science and Technology Support Program of the Department of Science and Technology of Sichuan Province (2014ZS0043)

Background: Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism has been speculated to be and extensively investigated as a risk factor for various vascular diseases, including intracerebral hemorrhage (ICH). However, results from published studies regarding the role of C677T polymorphism in ICH risk in Chinese populations were contradictory rather than conclusive.

Material/Methods: In this study, a total of 180 ICH patients and 180 matched controls of Chinese Han ethnicity were enrolled. The MTHFR C677T polymorphism was genotyped by polymerase chain reaction-ligation detection reaction (PCR-LDR). A meta-analysis was conducted by combining our data with previous relevant studies in Chinese populations.

Results: In our case-control study, similar allele frequency (p=0.492) and genotype distribution (p=0.748) of MTHFR C677T polymorphism were detected between ICH patients and controls. Further analysis based on hematoma location did not show a significant association. When combined with previous studies, however, C677T polymorphism was found to be significantly associated with an increased risk for ICH in Chinese populations (recessive model: OR=1.57, 95%CI=1.29–1.91). When focusing on the Han ethnicity, carriers of the TT genotype had an increased risk of ICH (recessive model: OR=1.36, 95%CI=1.05–1.75).

Conclusions: In this case-control study we did not observe that the MTHFR C677T polymorphism was associated with ICH risk in people of Chinese Han ethnicity. However, when combined with previous published studies, a significant association of C677T polymorphism with an increased risk of ICH was detected in Chinese populations, and also in the subgroup analysis focusing on Han ethnicity.

MeSH Keywords: Cerebral Hemorrhage • China • Methylenetetrahydrofolate Reductase (NADPH2) • Polymorphism, Single Nucleotide
Background

Spontaneous intracerebral hemorrhage (ICH) is a devastating disease with an overall incidence of 24.6 per 100,000 person-years [1]. It accounts for 10–15% of all strokes, leading to a catastrophic consequence. The mortality of ICH at 1 month was 35–52% and only 20% regained functional independence by 6 months [2]. Hypertension, low cholesterol levels, heavy alcohol intake, advanced age, and male gender have been identified as important risk factors for ICH [3]. However, these conventional risk factors could not explain all cases of ICH. On the other hand, genome-wide association studies and large-scale genetic association studies have indicated an important role of genetic factors in ICH pathogenesis [4–6].

Homocysteine (Hcy) is a metabolite of the essential amino acid methionine. Elevated Hcy has been associated with various vascular diseases, including coronary artery disease, venous thrombosis, and stroke [7,8]. Although not fully understood, endothelial dysfunction related to hyperhomocysteinemia has been suggested as one of the mechanisms [9].

Methylenetetrahydrofolate reductase (MTHFR), encoded by MTHFR gene, is a crucial enzyme regulating intracellular Hcy and folate metabolism. MTHFR catalyzes the transformation of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which serves as the methyl group donor for converting homocysteine into methionine [10,11]. The most investigated polymorphism in MTHFR gene is C677T, which can lead to the replacement at codon 222 for alanine to valine, causing increased thermolability and reduced activity of enzyme MTHFR and, subsequently, an elevated plasma level of Hcy [12]. MTHFR C677T polymorphism has been speculated to be and extensively investigated as a risk factor for various vascular diseases, including ICH [13,14]. However, results from published genetic-association studies were contradictory rather than conclusive. Some reported a significant impact of C677T polymorphism on ICH risk [15, 16] while some failed to replicate these findings [17,18].

Here, we conducted a case-control study to evaluate the influence of MTHFR C677T polymorphism on ICH risk. Furthermore, since ICH incidence is heterogeneous among different Chinese populations [19,20], this case-control study included subjects of Chinese Han ethnicity only. In addition, a meta-analysis was performed integrating data from the present samples and those available from previous studies focusing on Chinese populations.

Material and Methods

Study subjects

Consecutive adult CT-proved ICH patients of Chinese Han ethnicity admitted to West China Hospital of Sichuan University were enrolled in this study from November 2011 to September 2012. We excluded patients with secondary ICH due to brain tumor, aneurysm, vascular malformation, head trauma, hemorrhagic transformation of cerebral infarction, coagulation disorder, or concurrent use of anticoagulation. Age-, sex-, and ethnicity-matched control subjects without history of ICH were recruited from those undergoing routine health examinations in our hospital. The following demographic and clinical data were collected from medical records of each participant: age, sex, hypertension, diabetes mellitus, hyperlipidemia, alcohol consumption, and smoking. Hematoma location was classified as lobar or deep (basal ganglia, thalamus, brain stem and cerebellum). This study was approved by the Ethics Committee of West China Hospital of Sichuan University. Written informed consents were obtained from all participants or their legal surrogates.

Genotyping

DNA was isolated from peripheral whole blood using the DNA Blood Kit (Biotekie Corp., China). The C677T polymorphism was genotyped by the polymerase chain reaction-ligase detection reaction (PCR-LDR) sequencing method, as described previously [21]. Briefly, the PCR primers used were: 5'-AGGCCAGCCTCTCCTGACTGT-3' (forward) and 5'-CATGTCGGTGCATGCCTTCA-3' (reverse). The PCR protocol was: an initial denaturation step of 5 min at 95°C, 35 cycles of extension step of 72°C for 10 min.

The following LDR was carried out in a total volume of 10μl, containing 3 μl PCR product, 1 μl 10×Taq DNA ligase buffer, 2 U of Taq DNA ligase (NEB), and 0.1 pmol of each probe. LDR probes were composed of 1 common probe and 2 discriminative probes. The LDR protocol was: 95°C for 2 min, 35 cycles of 94°C for 15 s, 55°C for 15 s, and 72°C for 30 s, and a final extension step of 72°C for 10 min.

The following LDR was carried out in a total volume of 10μl, containing 3 μl PCR product, 1 μl 10×Taq DNA ligase buffer, 2 U of Taq DNA ligase (NEB), and 0.1 pmol of each probe. LDR probes were composed of 1 common probe and 2 discriminative probes. The LDR protocol was: 95°C for 2 min, 35 cycles of 94°C for 15 s, 55°C for 15 s, and 72°C for 30 s, and a final extension step of 72°C for 10 min.

The following LDR was carried out in a total volume of 10μl, containing 3 μl PCR product, 1 μl 10×Taq DNA ligase buffer, 2 U of Taq DNA ligase (NEB), and 0.1 pmol of each probe. LDR probes were composed of 1 common probe and 2 discriminative probes. The LDR protocol was: 95°C for 2 min, 35 cycles of 94°C for 15 s, 55°C for 15 s, and 72°C for 30 s, and a final extension step of 72°C for 10 min.

The following LDR was carried out in a total volume of 10μl, containing 3 μl PCR product, 1 μl 10×Taq DNA ligase buffer, 2 U of Taq DNA ligase (NEB), and 0.1 pmol of each probe. LDR probes were composed of 1 common probe and 2 discriminative probes. The LDR protocol was: 95°C for 2 min, 35 cycles of 94°C for 15 s, 55°C for 15 s, and 72°C for 30 s, and a final extension step of 72°C for 10 min.

Statistical analysis

Hardy-Weinberg equilibrium (HWE) in the control subjects was tested by a goodness-of-fit chi-squared test. Differences in baseline characteristics, genotype distribution, and allele frequency between ICH patients and controls were evaluated using the t test or χ² test, as appropriate. Multiple regression
analysis was used to assess the independent impact of C677T polymorphism after adjusting for age, sex, hypertension, diabetes, hyperlipidemia, smoking, and alcohol consumption. The alternative genetic models for the C677T polymorphism included alleles (T vs. C) and genotypes for codominant, dominant, and recessive models. Stratified analyses according to the hematoma location (lobar or deep) were also conducted. Statistical analysis was performed with SPSS for Windows, version 18.0 (SPSS Inc., Chicago, IL, USA). Results were considered significant when \( P<0.05 \) (2-sided).

### Meta-analysis

A meta-analysis was performed combining our data with previous published studies to further investigate the association of MTHFR C677T polymorphism with ICH risk in Chinese populations. We searched PubMed, Embase, and China National Knowledge Infrastructure (CNKI) databases until July 2015 to screen for relevant genetic association articles. The following search terms were used: intracerebral hemorrhage, hemorrhagic stroke, MTHFR, methylenetetrahydrofolate reductase, polymorphism, genotype, variant, and mutation. The search result was supplemented by screening references of retrieved articles and relevant reviews.

The inclusion criteria were: (1) a case-control design; (2) conducted in a Chinese population; (3) provided information on genotype frequencies or sufficient data to calculate them; (4) genotype distribution in control group was in accordance with HWE. For studies with overlapping subjects, only the one with the most complete dataset was included. For each included study, the following data were extracted: authors, year of publication, province, age, sex, sample size, source of control, matching criteria, and genotype distribution.

The association of C677T polymorphism with ICH risk in Chinese populations was evaluated by calculating pooled ORs with 95% CIs. We used Cochran’s \( Q \) test and \( I^2 \) statistic to assess between-study heterogeneity. When substantial heterogeneity was detected (\( P<0.05 \) for \( Q \) test or an \( I^2 >50% \)), we used a random-effects model to assess the influence of genotype on ICH risk [22]. Otherwise, a fixed-effects model was applied [23]. To test the robustness of the findings, we performed sensitivity analysis by sequentially omitting each study. We assessed the potential publication bias visually by estimating the possible skewness in a funnel plot [24] and statistically with the methods described by Egger [25]. The latter is a weighted linear regression of standard normal deviates against the inverse of the standard error. The intercept of the regression is applied to measure the degree of funnel plot asymmetry [23].

### Results

#### Case-control study

In total, we enrolled 180 patients and 180 healthy controls. Baseline characteristics are summarized in Table 1. Mean age was 57.7±14.1 years for ICH patients and 57.0±9.7 years for controls.

Genotype distribution in the controls was in accordance with HWE (\( P=0.903 \)). No significant difference was observed regarding the genotype distribution (\( P=0.748 \)) or \( T \) allele frequency (\( P=0.492 \)) between the ICH patients and healthy controls (Table 2). When stratified by hematoma location, no significant difference in genotype frequencies between ICH patients and controls was detected in lobar ICH (\( P=0.193 \)) or in deep ICH (\( P=0.682 \)). In the multiple logistic regression model adjusted for age, sex, hypertension, diabetes, hyperlipidemia, smoking, and alcohol consumption, no significant association of C677T polymorphism with ICH risk was detected in allelic, codominant, dominant, or recessive models (Table 3).

#### Meta-analysis

After a comprehensive literature search and records screening, full texts of 16 studies were included for further evaluation.
Eight studies were then excluded: five for departure from HWE [26–30], one for insufficient data [31], one [32] for duplication with another study [28], and one for Mongolian population [33]. One more eligible study was detected through screening reference lists of achieved studies and reviews [34]. Finally, nine previous studies together with the current study, forming a total of 1030 ICH patients and 1474 controls, were enrolled in this meta-analysis [15,16,34–40] (Table 3). Overall, a significant association between C677T polymorphism and ICH risk in Chinese populations were observed (dominant model: OR=1.57, 95%CI=1.29–1.91, Table 4, Figure 1). When focusing on the Chinese Han population, a significant association was

| Genotype | Control (n=180) | Total ICH (n=180) | Lobar ICH (n=47) | Deep ICH (n=133) | OR (95% CI) Total ICH vs. control | OR (95% CI) Lobar ICH vs. control | OR (95% CI) Deep ICH vs. control |
|----------|----------------|------------------|-----------------|-----------------|---------------------------------|---------------------------------|---------------------------------|
| CC       | 64 (35.6)      | 71 (39.4)        | 20 (42.6)       | 51 (38.3)       | 1.00                            | 1.00                            | 1.00                            |
| CT       | 86 (47.8)      | 81 (45.0)        | 24 (51.1)       | 57 (42.9)       | 0.865 (0.54, 1.39)              | 0.89 (0.45, 1.76)               | 0.84 (0.50, 1.42)               |
| TT       | 30 (16.7)      | 28 (15.6)        | 3 (6.4)         | 25 (18.8)       | 0.77 (0.41, 1.47)              | 0.29 (0.08, 1.10)               | 1.05 (0.53, 2.07)               |
| C        | 214 (59.4)     | 223 (61.9)       | 64 (68.1)       | 159 (59.8)      | 1.00                            | 1.00                            | 1.00                            |
| T        | 146 (40.6)     | 137 (38.1)       | 30 (31.9)       | 107 (40.2)      | 0.87 (0.64, 1.19)              | 0.66 (0.41, 1.08)               | 0.98 (0.70, 1.38)               |
| Dominant | 116 (64.4)     | 109 (60.6)       | 27 (57.4)       | 82 (61.7)       | 0.84 (0.54, 1.31)              | 0.71 (0.36, 1.37)               | 0.89 (0.55, 1.46)               |
| Recessive| 150 (83.3)     | 152 (84.4)       | 44 (93.6)       | 108 (81.2)      | 0.84 (0.47, 1.51)              | 0.31 (0.09, 1.10)               | 1.15 (0.62, 2.14)               |

Table 2. Association between MTHFR C677T polymorphism and ICH risk.

Table 3. Characteristics of studies included in the meta-analysis.

| Author    | Year | Province | Han ethnicity | No. (case/control) | Source of control | Match criteria | Case | Control |
|-----------|------|----------|---------------|--------------------|------------------|---------------|------|---------|
| Fang [15] | 2004 | Jilin     | Yes           | 27/96              | PB               | NA            | 7    | 10      |
| Fu [35]   | 2005 | Shanghai | NA            | 26/50              | PB               | Age, gender   | 10   | 13      |
| Hu [36]   | 2007 | Inner Mongolia | No | 32/115         | PB               | Age, gender   | 11   | 12      |
| Xiao [37] | 2006 | Shanghai | NA            | 61/100             | PB               | NA            | 12   | 33      |
| Zhang [38]| 2004 | Shanghai | NA            | 94/100             | PB               | Gender        | 21   | 59      |
| Zhang [39]| 2004 | Beijing  | Yes           | 156/239            | PB               | Smoking, drinking | 37   | 68      |
| Zhang [40]| 2008 | Beijing  | Yes           | 222/282            | PB               | Current smoking, alcohol drinking | 57   | 103     |
| Zhao [16] | 2001 | Northern | NA            | 202/190            | NA               | Age, gender, blood pressure | 29   | 85      |
| Zheng [34]| 2000 | Hunan    | NA            | 30/122             | PB               | Gender        | 17   | 10      |
| This study| 2015 | Sichuan  | Yes           | 180/180            | PB               | Age, gender   | 71   | 81      |

NA – not available; PB – population-based.
detected in the recessive model (dominant model: OR=1.36, 95%CI=1.05–1.75). When combining studies with population-based controls, C677T polymorphism was found to be significantly associated with an increased ICH risk (OR=1.39, 95%CI=1.09–1.77). When stratified by match status, we also detected a significant role of C677T polymorphism in ICH susceptibility (OR=1.29, 95%CI=1.05–1.59). In sensitivity analysis, we repeated the meta-analysis by omitting each study sequentially and found that the results did not change substantially under the genetic models except for the heterozygous codominant model. The funnel plots (Figure 2) and Egger’s test (data not shown) suggested that there was no publication bias in the present meta-analysis.

**Discussion**

Despite advances in neurocritical care in recent decades, ICH remains a devastating disease causing substantial death and chronic disability. This status highlights the critical role of primary and secondary preventive strategies, which is now most promising for reducing the burden imposed by ICH. However, the current limited understanding of ICH pathogenesis remains a formidable barrier to the development of these strategies [41]. Data on familial aggregation suggests the role of genetics in ICH pathogenesis [42].

| Variables | N | Case/control | T vs. C | TT vs. CC | CT vs CC | TT+CT vs CC | TT vs CT+CC |
|-----------|---|---------------|---------|-----------|----------|-------------|-------------|
|           |   |               | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Total     | 10 | 1030/1474     | 1.42 (1.14, 1.77) | 0.001 | 1.97 (1.31, 2.95) | 0.009 | 1.23 (1.01, 1.49) | 0.054 | 1.49 (1.09, 2.05) | 0.005 | 1.57 (1.29, 1.91) | 0.164 |
| Han ethnicity | 4 | 585/797 | 1.18 (0.92, 1.51) | 0.080 | 1.31 (0.97, 1.77) | 0.147 | 0.95 (0.74, 1.23) | 0.791 | 1.06 (0.83, 1.34) | 0.365 | 1.36 (1.05, 1.75) | 0.177 |
| Population-based | 9 | 828/1284 | 1.39 (1.09, 1.77) | 0.002 | 1.89 (1.20, 2.96) | 0.012 | 1.26 (0.92, 1.73) | 0.049 | 1.44 (1.02, 2.02) | 0.008 | 1.49 (1.19, 1.86) | 0.148 |
| Match | 8 | 942/1278 | 1.29 (1.05, 1.59) | 0.018 | 1.57 (1.23, 2.01) | 0.052 | 1.13 (0.92, 1.39) | 0.203 | 1.31 (0.98, 1.74) | 0.049 | 1.48 (1.21, 1.82) | 0.227 |

N – number of datasets in the meta-analysis; \( P_{\text{het}} \) – \( P \) value of Q-test for heterogeneity test.

**Figure 1.** Forest plot for association of MTHFR C677T polymorphism with ICH risk (TT vs. CT+CC).

**Figure 2.** Funnel plot for publication bias test (TT vs. CT+CC).
In our case-control study, we detected a similar genotype distribution regarding MTHFR C677T polymorphism between ICH patients and healthy controls in the Chinese Han population. However, when combined with previously published data, we found a significant association between this polymorphism and an increased ICH risk in Chinese populations. The association remained significant when confined to Han ethnicity, studies using matched controls, and studies including population-based controls. The impact of MTHFR C677T polymorphism on ICH risk has also been evaluated in other populations, with conflicting results. Hultdin et al., investigating Swedish cohorts, reported that MTHFR TT carriers had a 3.62-fold higher risk of hemorrhagic stroke when compared with CC carriers after adjusting for other confounding factors [43]. However, Dikmen et al. did not detect any significant role of C677T polymorphism in hemorrhagic stroke risk in a Turkish population [44]. Ethnic, environmental, and socioeconomic factors might partially contribute to this discrepancy.

In vivo and in vitro studies suggested that subjects homozygous for the T allele have significantly elevated Hcy levels [12,45]. It is generally accepted that elevated Hcy status can induce endothelial dysfunction. Interestingly, some studies, although still controversial, observed significant associations of MTHFR C677T polymorphism with increased risk of ischemic stroke [46,47]. Moreover, elevated tHcy has also been associated with development of ischemic stroke [48,49]. The explanation underlying this phenomenon was suggested to be that elevated Hcy can cause either ischemic stroke through its coagulative effect or ICH through promoting plaque rupture [28].

One plausible application of genetic information on ICH susceptibility is its potential to improve risk assessment and thus to provide immediate clinical impact, such as decision-making regarding coagulation. However, the further application of MTHFR polymorphism, at least for coagulation adjustment, seems to be hampered by its dual effect on both ischemic stroke and ICH. Notably, ICH is a polygenic disease, with many genes thought to be involved, while a specific gene might make only a small contribution to ICH risk. We could not exclude the possibility that the ability to predict ICH would overwhelm ischemic stroke when incorporating C677T polymorphism into other specific genetic or environmental risk factors. Therefore, MTHFR C677T polymorphism still has the potential to contribute to the construction of future risk assessment algorithms.

Several limitations should be addressed when interpreting our results. Firstly, some studies, including one multicenter case-control study, were excluded due to deviation from HWE. Secondly, although it was mentioned in all studies that participants were Chinese, it was not clearly if they were of Han ethnicity. Thus, only four studies were combined in the subgroup analysis focusing on the Chinese Han population. Thirdly, adjusted pooled ORs could not be calculated due to the limited information available in the included studies. Fourthly, although it is suggested that cerebral amyloid angiopathy might contribute to lobar ICH, while deep ICH is related to hypertensive vasculopathy, it remains unknown whether genes play different roles in lobar vs. deep ICH. However, the included studies did not perform further analysis based on hematoma location. Therefore, we could not calculate pooled ORs estimating the potential role of MTHFR C677T polymorphism in lobar ICH and deep ICH, respectively. Fifthly, the sample size in our case-control study was relatively small. However, this study has some strengths. Firstly, this is the first meta-analysis evaluating the role of MTHFR C677T polymorphism in ICH risk in Chinese populations. Secondly, we performed detailed subgroup analysis, including focusing on Chinese Han ethnicity.

Conclusions

In the present case-control study, we did not observe that MTHFR C677T polymorphism is associated with ICH risk in the Chinese Han population. However, when combined with previously published studies, a significant association of C677T polymorphism with an increased risk of ICH was detected in Chinese populations, and also in the subgroup analysis focusing on Han ethnicity.

Competing interests

The authors declared no competing interests.

References:

1. van Asch CJ, Luitse MJ, Rinkel GJ et al: Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: A systematic review and meta-analysis. Lancet Neurol, 2010; 9: 167–76
2. European Stroke Initiative Writing C, Writing Committee for the EEC, Steiner T, et al: Recommendations for the management of intracranial haemorrhage – part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis, 2006; 22: 294–316
3. Rincon F, Mayer SA: Clinical review: Critical care management of spontaneous intracerebral hemorrhage. Crit Care, 2008; 12: 237
4. Anderson CD, Biffi A, Nalls MA et al: Common variants within oxidative phosphorylation genes influence risk of ischemic stroke and intracerebral hemorrhage. Stroke, 2013; 44: 612–19
5. Woo D, Falcone GI, Devan WI et al: Meta-analysis of genome-wide association studies identifies 1q22 as a susceptibility locus for intracranial hemorrhage. Am J Hum Genet, 2014; 94: 511–21
6. Biffi A, Sonni A, Anderson CD et al: Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol, 2010; 68: 934–43
7. Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ, 2002; 325: 1202
28. Li Z, Sun L, Zhang H et al: Elevated plasma homocysteine was associated with thromboembolism. Thromb Res, 2013; 132: 170–74

29. Chen SD, Zhang WL, Sun K et al: Interaction of genetic risk factors confers higher risk for thrombotic stroke in male Chinese: A multicenter case-control study. Ann Hum Genet, 2007; 71: 620–29

30. Zhou BS, Bu GY, Li M et al: Tagging SNPs in the MTHFR gene C677T and A1298C with primary hypertension disease and hypertension complications. Cerebrovasc Dis, 2010; 29: 454–59

31. Hu X, Li J, Qin X et al: Hemostatic changes in relation to plasma homocysteine and methylenetetrahydrofolate reductase C677T polymorphism: Evidence for an association with arterial and venous thrombosis in the Chinese population. Pathol Oncol Res, 2005; 21: 21–22

32. Huo Y, Li J, Qin X et al: The relationship between MTHFR gene polymorphism and hemorrhagic stroke. Zhong Guo Lao Nian Yi Xue Za Zhi, 2005; 24: 413–17

33. Rost NS, Greenberg SM, Rosand J: The genetic architecture of intracerebral hemorrhage: A prospective study in North Carolina. Neuroepidemiology, 2002; 21: 18–21

34. Hultdin J, Van Guelpen B, Winkvist A et al: Prospective study of first stroke in relation to plasma homocysteine and MTHFR C677T and 1298A>C genotypes and haplotypes – evidence for an association with hemorrhagic stroke. Clin Chem Lab Med, 2011; 49: 1555–62

35. Du X, Zhang Q, Li M et al: Homocysteine, ischemic stroke, and coronary heart disease in hypertensive patients: A population-based, prospective cohort study. Stroke, 2015; 46: 1777–86

36. Zuo W, Wu Q, Wang C et al: Homocysteine, ischemic stroke, and coronary heart disease in hypertensive patients: A population-based, prospective cohort study. Stroke, 2015; 46: 1777–86

37. Dikmen M, Ozbalbaki D, Gunes HV et al: Acute stroke in relation to homocysteine and methylenetetrahydrofolate reductase gene polymorphisms. Acta Neurol Scand, 2006; 113: 307–14

38. Zhou BS, Bu GY, Li M et al: Tagging SNPs in the MTHFR gene and risk of ischemic stroke in a Chinese population. Int J Mol Sci, 2014; 15: 8931–40

39. Zhang J, Lu L, Shi H et al: The relationship between MTHFR gene polymorphism and cerebral hemorrhage. Zhong Guo Lao Nian Yi Xue Za Zhi, 2004; 17: 267–69

40. Zhang Y, Xie R, Chen DF, Fu Y: Association of methylenetetrahydrofolate reductase polymorphism with cerebral hemorrhage. Zhong Hua Liu Xing Bing Xue Za Zhi, 2004; 25: 44–7

41. Alberts MJ, McCarron MO, Hoffmann KL, Graffagnino C: Familial clustering of intracerebral hemorrhage: A prospective study in North Carolina. Neuroepidemiology, 2002; 21: 18–21

42. Hultdin J, Van Guelpen B, Winkvist A et al: Prospective study of first stroke in relation to plasma homocysteine and MTHFR C677T and 1298A>C genotypes and haplotypes – evidence for an association with hemorrhagic stroke. Clin Chem Lab Med, 2011; 49: 1555–62

43. Dikmen M, Ozbalbaki D, Gunes HV et al: Acute stroke in relation to homocysteine and methylenetetrahydrofolate reductase gene polymorphisms. Acta Neurol Scand, 2006; 113: 307–14

44. Zou HB, Bu GY, Li M et al: Tagging SNPs in the MTHFR gene and risk of ischemic stroke in a Chinese population. Int J Mol Sci, 2014; 15: 8931–40

45. Moe KT, Woon FP, De Silva DA et al: Association of acute ischemic stroke with the MTHFR C677T polymorphism but not with NOS3 gene polymorphisms in a Singapore population. Eur J Neurol, 2008; 15: 1309–14

46. Isoldia-Salas I, Barinagarrementeria-Aladaz F, Leanos-Miranda A et al: The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with idiopathic ischemic stroke in the young Mexican-Mestizo population. Cerebrovasc Dis, 2010; 29: 454–59

47. Han L, Wu Q, Wang C et al: Homocysteine, ischemic stroke, and coronary heart disease in hypertensive patients: A population-based, prospective cohort study. Stroke, 2015; 46: 1777–86

48. Sacco RL, Andaz K, Lee HS et al: Homocysteine and the risk of stroke in a triethnic cohort: The Northern Manhattan Study. Stroke, 2004; 35: 2263–69